Caen Cedex 5

• HARMONi-3 Not authorised
  2023-504989-37-00 5 Metastatic Squamous Non-small Cell Lung Cancer
• Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemo … Pending
  2023-508658-24-00 4 type B3 thymoma and thymic carcinoma
• Study of the effect and tolerability of INT230-6 by direct injection into the tumor, followed by neoadjuvant treatment with chemoimmunothera … Pending
  2024-512511-49-00 4 Early triple-negative breast cancer (TNBC)
• Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients Pending
  2024-514144-85-02 3 Glioblastoma
• LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy Pending
  2024-515340-23-00 4 Colon cancer
• TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phas … Pending
  2024-516182-37-01 4 Maintenance treatment in patients with locally advanced/metastatic uro
• A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cance … Pending
  2024-519787-40-00 5 Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal C
• Evaluation study of a treatement with Nivolumab and Ipilimumab or tKi according to molecular group in naïve metastatic Kidney cancer Pending
  2024-520045-23-00 4 Kidney cancer
• Impact of the timing of immunotherapy administration in metastatic lung cancers Pending
  2025-521891-78-00 5 Adult patients with stage IV non squamous non-small cell lung cancer (
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Urinary Bladder Neoplasms
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 4 Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
• TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer. Pending
  2025-524213-84-00 5 Patients with advanced or metastatic ER+ HER2- breast cancer
• REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Res … Pending
  2025-524232-20-00 7 Patients with poor prognostic ovarian cancers based on the tumor prima
• A Research Study Testing New Cancer Medicines Used Alone or Together to Treat Solid Tumors Pending
  2025-524623-50-00 9 Solid Tumors
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Recruiting
  2025-520565-51-00 5 2026-06-23 small cell lung cancer
• A clinical trial of MK-1084 and durvalumab in people with non-small cell lung cancer (MK-1084-015) Recruiting
  2025-522038-29-00 5 2026-06-16 Locally advanced, unresected (unresectable or medically inoperable or
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting
  2024-519655-28-00 5 2026-04-23 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting
  2025-521514-26-00 5 2026-01-26 Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
• A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting
  2023-507525-42-00 5 2025-12-23 Endometrial cancer
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting
  2025-521040-37-00 5 2025-11-26 HER2-positive early breast cancer
• A Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy … Recruiting
  2025-521511-40-00 10 2025-11-18 metastatic non-small cell lung cancer

Showing 1–24 of 287 trials